Letter of concern about Chempartner Pharmatech Co.Ltd(300149)
Gem concern letter [2022] No. 92 Chempartner Pharmatech Co.Ltd(300149) board of directors:
On the evening of January 28, 2022, your company disclosed the annual performance forecast for 2021. It is estimated that the net profit attributable to the shareholders of the listed company in 2021 will be a loss of 394.8306 million yuan to 584.8306 million yuan. The announcement said that there were obvious signs of impairment of the company's goodwill during the reporting period. According to the accounting standards for business enterprises and other relevant regulations, based on the principle of prudence, the company made an asset impairment provision of 300 million to 450 million yuan for goodwill. The goodwill of your company was formed by the early acquisition of Shanghai Ruizhi Chemical Research Co., Ltd. (hereinafter referred to as "Shanghai Ruizhi"), involving an original value of 1.617 billion yuan. Our department is concerned about this. Please explain the following matters after careful verification: 1 In 2020, Shanghai Ruizhi realized a net profit of 164.747 million yuan attributable to the shareholders of the parent company after deducting non recurring profits and losses, and the achievement rate of performance commitment was 68.93%. The net profit of Shanghai Ruizhi in the first half of 2021 was a loss of 3.8728 million yuan, a sharp decrease of 109.87% compared with the same period in 2020. Please explain in detail the reasons and rationality of the rapid decline in performance after the performance commitment period of Shanghai smart in combination with the development of the industry, competition pattern and market position, and whether there is any false increase in income in the early stage, cross period recognition of income, etc, Combined with the quarterly performance changes of Shanghai Ruizhi in 2021, this paper explains the specific process of identifying and judging the signs of goodwill impairment of relevant asset groups of Shanghai Ruizhi in 2021, the time point when the signs of goodwill impairment appear for the first time, and whether the company conducts goodwill impairment test in time and prompts relevant risks.
2. At the end of 2020, your company accrued a goodwill impairment of 42 million yuan for the goodwill involved in Shanghai Ruizhi. Please compare the differences between the key parameters and key assumptions (including but not limited to the forecast period, operating income growth rate, net interest rate, discount rate, etc.) of the goodwill impairment test of Shanghai Ruizhi at the end of 2020 and 2021, and analyze and explain the reasons and rationality of the differences, Combined with the actual performance of Shanghai Ruizhi and the profit forecast of goodwill impairment test in the early stage, it explains whether the provision for goodwill impairment in the early stage is sufficient.
3. Other matters that your company deems necessary to explain.
Please make a written statement on the above matters, submit the relevant explanatory materials to our department for disclosure before February 11, 2022, and send a copy to the listed company supervision division of Guangdong securities regulatory bureau.
At the same time, remind your company that listed companies must earnestly and timely fulfill the obligation of information disclosure in accordance with national laws and regulations and the Shenzhen Stock Exchange GEM Listing Rules. All members of the board of directors of a listed company must ensure that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint liabilities for their guarantee.
This is to inform you.
Gem company management department
January 29, 2022
